At 2020 Korea Bio Investment Conference, Dong-Hoon Jin, CEO of Wellmarker Bio announced its Phase I clinical trial plan. “One of our main technology is Predictive biomarker. It is an indicator such as DNA, proteins that can measure the biological state or condition of the body. Based on patients’ biomarker, we can foresee the drug’s efficacy before administration”, cited Jin. He also mentioned that “Biomarker based anti-cancer drug development is expected to to triple the likelihood of approval”.
Wellmarker Bio is planning to initiate phase 1a and 1b clinical trial of colon cancer drug 'WM-S1’ in Australia and in the United States after completing the preclinical study. Another lead asset WM-A1, a first-in-class liver cancer drug is currently developed as an immunotherapy and will enter preclinical study in 2021.
Link: The Korea Economic Daily(https://www.hankyung.com/it/article/202012284118i)